Greenbrook TMS Inc. ("Greenbrook" or the "Company") is pleased to announce that the Company has obtained a final order from the Ontario Superior Court of Justice (Commercial List) approving the ...

Seasonal Affective Disorder (SAD) affects millions of Americans, and cases usually start to rise in late fall or early winter ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

'Functional unblinding was a major barrier to the approval of psychedelics as medicines to treat the patients who need them most,' said Dr. Andrew Chadeayne, CaaMTech CEO. 'I'm incredibly proud that ...

Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

People who feel more fatigued, sad, irritable and hungry as the days darken from fall into winter may benefit from using a ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...